ABBV vs AMAT: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Applied Materials, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-06.
AbbVie Inc. · Healthcare
$261.07
+1.2% upside to fair value
Grade C
High Quality
VS
Applied Materials, Inc. · Technology
$603.04
-45.0% upside to fair value
Grade C
High Quality
QuantHub Verdict
ABBV has more upside to fair value
(+1.2%).
AMAT trades at a lower forward P/E
(56.4x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
AMAT |
| Current Price |
$261.07 |
$603.04 |
| Fair Value Estimate |
$264.30 |
$331.67 |
| Upside to Fair Value |
+1.2%
|
-45.0%
|
| Market Cap |
$461.3B |
$478.8B |
| Forward P/E |
128.0x
|
56.4x
|
| EV / EBITDA |
31.0x
|
43.0x
|
| Price / Sales |
7.3x
|
16.5x
|
| Price / FCF |
22.1x
|
80.3x
|
| Revenue Growth YoY |
+12.4%
|
+11.4%
|
| Gross Margin |
70.7%
|
49.0%
|
| Operating Margin |
27.6%
|
29.5%
|
| Return on Equity |
68.0%
|
39.8%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
4.52%
|
1.25%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology and aesthetics. The company is transitioning from its historical Humira dominance, which has faced loss of exclusivity, toward high-growth assets like Skyrizi and Rinvoq that are driving robust revenue growth of 12.4% in the most recent quarter. Despite strong revenue growth and a dura…
Applied Materials, Inc. is a leading semiconductor equipment company with a strong competitive moat in multiple wafer fab equipment segments, driven by its scale, infrastructure, and technology leadership in AI-critical process steps. The company benefits from a seasoned management team led by CEO Gary Dickerson, who has over 12 years at the helm and a track record of strong revenue and profitabi…
Accumulation Zones
| Metric |
ABBV |
AMAT |
| Zone Low |
$198.23 |
$248.75 |
| Zone High |
$224.66 |
$281.92 |
| In Buy Zone? |
No
|
No
|